CJC-1295 No DAC + Ipamorelin calculator
The most common growth-hormone secretagogue pairing, combining a GHRH analog with a ghrelin-mimetic. Neither component is approved; the blend is unregulated.
Also known as: CJC/Ipamorelin blend, GH secretagogue stack
FDA status — not an approved drug Not FDA-approved. Both CJC-1295 and ipamorelin are in Category 2 of FDA's bulk drug substances list, and the combination has not been studied.
Schedule CJC-1295 No DAC + Ipamorelin → Set your dosing schedule and get a phone notification when each dose is due. Free.
What CJC-1295 No DAC + Ipamorelin is
CJC-1295 (no DAC) with ipamorelin is the most widely used growth-hormone secretagogue stack. It pairs a GHRH analog with a ghrelin-mimetic to stimulate the pituitary through two receptor pathways at once. Both components are unapproved, and the combination has not been studied in trials.
Research depth: 2/5 Reasonable mechanistic rationale and component-level data, but no trials of the combination. Human trials: None for the combination. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How CJC-1295 No DAC + Ipamorelin works
The two peptides hit complementary pituitary receptors: CJC-1295 activates GHRH receptors while ipamorelin activates ghrelin/GHSR receptors. Because growth-hormone release integrates both signals, combining them is intended to produce a stronger, more natural pulse. Whether the combination is more effective or as safe as the components alone is untested.
CJC-1295 No DAC + Ipamorelin side effects
Commonly reported
- Injection-site reactions
- Flushing and headache
- Water retention
- Increased hunger
- Drowsiness after dosing
Serious — seek medical care
- No studies of the combination — interactions unknown
- Sustained GH elevation raises insulin-resistance and fluid-retention concerns
- Prohibited in sport by WADA
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 200 mcg dose is then 0.04 mL — about 4 units on a 100-unit insulin syringe, giving roughly 50 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable CJC-1295 No DAC + Ipamorelin dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for CJC-1295 No DAC + Ipamorelin run from 100 mcg to 300 mcg. No established dosing exists for the combination — figures reflect the individual components' community doses, typically given together. There is no approved labeling for either.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use CJC-1295 No DAC + Ipamorelin at all are decisions for a licensed clinician who knows your history.
Common questions
Why combine CJC-1295 with ipamorelin?
They act on different pituitary receptors — CJC-1295 on GHRH receptors, ipamorelin on ghrelin (GHSR) receptors — so the pairing is intended to produce a larger, more physiologic growth-hormone pulse than either alone. The combination itself is unstudied.
Is this blend approved?
No. Neither component is approved, and the combination has no clinical evidence as a product. Both are prohibited in sport by WADA.